Eliminating Cellulite might not be possible on a metaphysical level - it is God's curse on man. I think they got the translation wrong in Genesis. The curse is not toiling with the sweat of your brow among thorns and thistles, but having to look at Cellulite.
But if God wil allow it, it's worth billions!
Holdings show you the winners and losers over time
Name Identifier Weight
Keryx Biopharmaceuticals Inc. KERX 3.02
Halozyme Therapeutics Inc. HALO 2.99
United Therapeutics Corporation UTHR 2.53
OPKO Health Inc. OPK 2.51
Incyte Corporation INCY 2.36
Cepheid CPHD 2.32
Alkermes Plc ALKS 2.29
Celldex Therapeutics Inc. CLDX 2.27
Gilead Sciences Inc. GILD 2.24
Isis Pharmaceuticals Inc. ISIS 2.18
Ligand Pharmaceuticals Incorporated LGND 2.17
Myriad Genetics Inc. MYGN 2.17
Pharmacyclics Inc. PCYC 2.16
Medivation Inc. MDVN 2.15
Alexion Pharmaceuticals Inc. ALXN 2.13
Biogen Idec Inc. BIIB 2.11
Celgene Corporation CELG 2.1
Regeneron Pharmaceuticals Inc. REGN 2.08
Alnylam Pharmaceuticals Inc ALNY 2.07
ACADIA Pharmaceuticals Inc. ACAD 2.06
Amgen Inc. AMGN 2.06
Cubist Pharmaceuticals Inc. CBST 2.02
Array BioPharma Inc. ARRY 1.96
Momenta Pharmaceuticals Inc. MNTA 1.93
Acorda Therapeutics Inc. ACOR 1.92
Exact Sciences Corporation EXAS 1.92
NPS Pharmaceuticals Inc. NPSP 1.92
Spectrum Pharmaceuticals Inc. SPPI 1.89
Aegerion Pharmaceuticals Inc. AEGR 1.87
BioMarin Pharmaceutical Inc. BMRN 1.84
Dendreon Corporation DNDN 1.79
InterMune Inc. ITMN 1.78
MannKind Corporation MNKD 1.77
Theravance Inc. THRX 1.77
TESARO Inc. TSRO 1.76
Arena Pharmaceuticals Inc. ARNA 1.75
ImmunoGen Inc. IMGN 1.74
Seattle Genetics Inc. SGEN 1.73
Exelixis Inc. EXEL 1.68
Insmed Incorporated INSM 1.68
Vertex Pharmaceuticals Incorporated VRTX 1.62
Clovis Oncology Inc. CLVS 1.61
Neurocrine Biosciences Inc. NBIX 1.5
Orexigen Therapeutics Inc. OREX 1.45
Ironwood Pharmaceuticals Inc. Class A IRWD 1.44
Infinity Pharmaceuticals Inc. INFI 1.38
Raptor Pharmaceutical Corp. RPTP 1.23
Genomic Health Inc. GHDX 1.2
Synageva Biopharma Corp GEVA 1.18
Sangamo BioSciences Inc. SGMO 1.12
Idenix Pharmaceuticals Inc. IDIX 0.81
Achillion Pharmaceuticals Inc. ACHN 0.78
Sarepta Therapeutics Inc. SRPT 0.74
Emergent BioSolutions Inc. EBS 0.57
AMAG Pharmaceuticals Inc. AMAG 0.44
ARIAD Pharmaceuticals Inc. ARIA 0.24
STATE STR INSTL LIQUID RES
Great new application in the aging baby-boom era.
Nov 11 (Reuters) - Halozyme Therapeutics Inc :
* Barclays raises price target to $12 from $8; rating equal weight
A 50% increase, and wiht their rationale of only counting approved products, perhaps useful as a bottom
Again, from Schwab's news on StreetSmart
But then again, Halozyme ALSO DOES make their own drugs.
Strong technology platform, potential monster shots on goal in diabetes as well as pancreatic and other cancers, becomes multiple revenue streams going forward. Artifical apncreas? Who knew? And a lot of the work done with other people's money.
Barring market disaster, 30s with in a year, not bad this far into the big run the market's had.
Even added more on the pullback into 11.60s late in the day.
Not sure if it's a buyout candidate because of the broad customer base. Sourcing from competitors is touchy.
Autoimmune is big.
Very similar platformy feel in autoimmune here in IDRA like you get with ACAD in psychosis.
Life changing stuff medically and financially.
Dwindling supply wiht the various large stakeholders. If we see the Baker Brotheres added this quarter . . .
Oct 4 (Reuters) - Idera Pharmaceuticals Inc :
* Healthcor management reports 5.6 percent passive stake in Idera
Pharmaceuticals Inc as of September 25 - SEC filing
Is this a first mention of ACAD by Cramer?
The Next Big Ideas
Investors looking for the next big investment ideas should look no further than the Russell 2000 small-cap index, Cramer told viewers. They'll find that over half of this year's biggest movers are biotechs, stocks that Cramer has championed for many years.
He said that biotechs are the quintessential anti-Washington stocks because they can prosper whether the government is open or closed.
Among the names that caught Cramer's attention were Acadia Pharmaceuticals(ACAD_), Celldex Threapeutics(CLDX_), Insys Threapeutics(INSY_), Keryx Biopharmaceuticals(KERX_), Clovis Oncology(CLVS_), Isis Pharmaceuticals(ISIS_) and NPS Pharmaceuticals(NPSP_).
Cramer said all of these names are smaller, more speculative investments, but all have the potential to become the next Celgene(CELG_) or Gilead Sciences(GILD_) and can make investors just as much money, even though they're already up huge for the year.
So that's where the 38.15 closing bid came from in AH. I'll have to watch the 11:00 version of Cramer.
Own CLDX and ACAD. Been paring off shares on the way up to not be greedy dammit!
BMRN and HALO too, and smaller amounts of IMMU, IMGN, CERS, ACRX
bought some crushed ACHN as an experiment today
Since it happened on 9/30, we'll see which side of this they took